- Home
- CRDF vs DOUG Comparison
CRDF vs DOUG Comparison
Compare CRDF & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- DOUG
- Stock Information
- Founded
- CRDF 1999
- DOUG 1911
- Country
- CRDF United States
- DOUG United States
- Employees
- CRDF N/A
- DOUG N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- DOUG Building operators
- Sector
- CRDF Health Care
- DOUG Real Estate
- Exchange
- CRDF Nasdaq
- DOUG Nasdaq
- Market Cap
- CRDF 133.5M
- DOUG 146.0M
- IPO Year
- CRDF N/A
- DOUG N/A
- Fundamental
- Price
- CRDF $4.96
- DOUG $1.83
- Analyst Decision
- CRDF Strong Buy
- DOUG
- Analyst Count
- CRDF 3
- DOUG 0
- Target Price
- CRDF $10.33
- DOUG N/A
- AVG Volume (30 Days)
- CRDF 3.9M
- DOUG 1.1M
- Earning Date
- CRDF 11-07-2024
- DOUG 11-07-2024
- Dividend Yield
- CRDF N/A
- DOUG N/A
- EPS Growth
- CRDF N/A
- DOUG N/A
- EPS
- CRDF N/A
- DOUG N/A
- Revenue
- CRDF $688,000.00
- DOUG $966,442,000.00
- Revenue This Year
- CRDF $23.78
- DOUG $5.28
- Revenue Next Year
- CRDF N/A
- DOUG $16.40
- P/E Ratio
- CRDF N/A
- DOUG N/A
- Revenue Growth
- CRDF 49.57
- DOUG 1.86
- 52 Week Low
- CRDF $1.30
- DOUG $1.00
- 52 Week High
- CRDF $6.42
- DOUG $3.16
- Technical
- Relative Strength Index (RSI)
- CRDF 72.82
- DOUG 39.19
- Support Level
- CRDF $3.06
- DOUG $1.82
- Resistance Level
- CRDF $5.64
- DOUG $2.47
- Average True Range (ATR)
- CRDF 0.45
- DOUG 0.18
- MACD
- CRDF 0.29
- DOUG -0.08
- Stochastic Oscillator
- CRDF 84.32
- DOUG 5.29
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees.